INTRODUCTION

About 15% of patients with end-stage renal disease (ESRD) have structural urinary tract abnormalities that may lead to lower urinary tract dysfunction [1,2]. Neurovesical dysfunction is one of the important causes of ESRD, and accounts for 20%–30% of ESRD in pediatric patients [3]. For the last several decades, there has been controversy about the safety of patients with augmentation for lower urinary tract dysfunction receiving renal transplantation because of the possibility of urinary tract infections (UTI) that can develop in immunosuppressed patients, leading to pyelonephritis and eventually graft loss. With the recent improvements in the management of lower urinary tract dysfunction, the outcomes of renal transplantation in these patients have improved [3].

It is now well known that in patients with bladders having a small volume and poorly compliance, bladder aug-
Renal transplantation after bladder augmentation surgery can lower bladder pressure, and protect the upper urinary tract and post-transplant allograft function [4]. We also published a case series with good mid-term outcomes [5,6]. However, there have been only a few reports on the long-term outcomes of kidney transplantation in patients with a history of augmentation cystoplasty. We analyzed our single-center experience in patients with renal transplantation after bladder augmentation and their long-term outcomes.

**METHODS**

This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2009-102-1157) and was conducted in accordance with the Declaration of Helsinki. The requirement for obtaining informed consent was waived by the Board.

Patients who received renal transplantation and had previously undergone augmentation cystoplasty or urinary diversion between January 1990 and May 2020 were retrospectively analyzed (Table 1). Nine patients were included in this study. Eight patients were male. The mean age at bladder augmentation was 17 years (range, 9–35 years). The average interval from bladder augmentation surgery to transplantation was 71 months (range, 2–240 months). The mean age at transplantation was 23 years (range, 10–51 years). The cause of ESRD was neurogenic bladder with myelomeningocele in six cases, renal tuberculosis in two cases, and bilateral reflux disease in one case. All patients could not self-void and required clean intermittent self-catheterization (CISC). Except for two patients, all patients underwent a primary operation to prevent vesicoureteral reflux, such as nephrostomy or ureteroneocystostomy, before the cystoplasty. However, all patients progressed to ESRD.

| Patient no. | Sex | Cause of ESRD | Age at cystoplasty (yr) | Source of reconstruction | Ureter implantation site | Appendixovesicostomy | Bladder capacity (mL) | Interval to transplant (mo) | Mode of dialysis | Duration of dialysis (yr) |
|-------------|-----|---------------|------------------------|--------------------------|-------------------------|---------------------|-----------------------|-------------------------|-----------------|------------------------|
| 1           | F   | Renal TBc     | 33                     | Ileal                    | Conduit                 | –                   | NA                    | 2                       | HD              | 0.1                    |
| 2           | F   | Renal TBc     | 13                     | Stomach, ileal           | Stomach                 | –                   | 300                   | 2                       | HD              | 3.0                    |
| 3           | F   | Renal Tbc     | 14                     | Stomach                  | Stomach                 | –                   | 130                   | 2                       | HD              | 1.2                    |
| 4           | F   | Renal Tbc     | 23                     | Stomach                  | Stomach                 | –                   | 400                   | 3                       | HD              | 3.5                    |
| 5           | M   | NB            | 19                     | Ileal                    | Native bladder          | –                   | 400                   | 5                       | HD              | 3.5                    |
| 6           | M   | NB            | 35                     | Ileal                    | Native bladder          | +                   | 500                   | 3                       | HD              | 3.5                    |
| 7           | M   | NB            | 9                      | Stomach                  | Native bladder          | –                   | 400                   | 5                       | HD       | 3.5                    |
| 8           | F   | NB            | 9                      | ileal                    | Native bladder          | +                   | 400                   | 5                       | HD              | 3.5                    |
| 9           | F   | MMC           | 10                     | ileal                    | Native bladder          | –                   | 100                   | 10                      | HD              | 4.0                    |

ESRD, end-stage renal disease; TBc, tuberculosis; PCKD, polycystic kidney disease; NB, neurogenic bladder; MMC, meningomyelocele; VUR, vesicoureteral reflux; PCN, percutaneous nephrostomy; UNC, ureteroneocystostomy; NA, not applicable; HD, hemodialysis; PD, peritoneal dialysis.
| Variable                          | Patient no. | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   |
|----------------------------------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Transplantation                  |             |     |     |     |     |     |     |     |     |     |
| Age at transplantation (yr)      |             | 33  | 13  | 10  | 26  | 20  | 51  | 11  | 10  | 30  |
| Donor type                       |             | LD  | LD  | LD  | DD  | LD  | DD  | LD  | LD  | LD  |
| Donor age (yr)                   |             | 60  | 41  | 42  | 16  | 49  | 65  | 38  | 42  | 57  |
| HLA mismatch                     |             | 3   | 3   | 2   | 0   | 1   | 5   | 3   | 2   | 3   |
| Immunosuppression                |             | CsA, Pd, (+MMF) | CsA, Pd, (-AZA) | TAC, Pd, MMF | TAC, Pd, MMF | TAC, Pd, MMF | TAC, Pd, MMF | TAC, Pd, MMF | TAC, Pd, MMF | TAC, Pd, MMF |
| Outcome                          |             |     |     |     |     |     |     |     |     |     |
| Follow-up (mo)                   |             | 341 | 259 | 185 | 175 | 148 | 148 | 126 | 49  | 2   |
| Serum creatinine (mg/dL)         |             | 5.64| 0.78| 6.78| 0.72| 0.95| 1.38| 1.36| 5.39| 1.06|
| Acute rejection                   |             | No  | No  | No  | No  | No  | Yes | No  | Yes | No  |
| Admission for febrile UTI        |             | 3   | 3   | 3   | 4   | 0   | 0   | 0   | 5   | 0   |
| Pathogens (>10⁵ CFU in urine)    | Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, E. coli, K. pneumoniae, E. aerogenes, M. morganii, Enterococcus Faecalis, Enterobacter cloacae | None | None | None | None | None | None | None | None |
| Graft failure                    |             | Yes | No  | Yes | No  | No  | No  | No  | Yes | No  |
| Graft survival time (mo)         |             | 302 | 259 | 107 | 175 | 148 | 148 | 126 | 35  | 2   |

Borderline change on protocol biopsy without renal dysfunction.

LD, living donor; DD, deceased donor; HLA, human leukocyte antigen; CsA, cyclosporine A; Pd, prednisolone; MMF, mycophenolate mofetil; AZA, azathioprine; TAC, tacrolimus; UTI, urinary tract infection; CFU, colony-forming unit.
RESULTS

Cystoplasty
Urological surgery for urinary bladder dysfunction was performed before renal transplantation. Four patients underwent cystoplasty using the ileum, two patients using the stomach, and the others using the ileocolic pouch and ureter. One patient underwent revision cystoplasty using the ileum because of the formation of a ureterovaginal fistula 8 years after the first operation using stomach. Vesico-ureteral reflux progressed in three patients. The bladder capacity increased to 100–400 mL after cystoplasty (Table 1).

Renal Transplantation
Renal transplantation was performed 71.3±95.2 months after cystoplasty. Eight patients received dialysis prior to transplantation for 4.7±3.9 years. Only one patient underwent pre-emptive transplantation. The baseline characteristics are summarized in Table 2. The mean age at renal transplantation was 23 years. Renal transplantation from living donors was performed in seven patients and from deceased donors in two patients. The mean number of HLA mismatches was 2.8, with types A, B, and DR. The immunosuppression regimen was cyclosporine-based in two patients, and a triple immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil or mycophenolic acid, and steroid in seven patients. During transplantation, ureter implantation was performed into the native bladder in six patients, the ileal conduit in one patient, and the bowel used for cystoplasty in two patients.

Complications and Clinical Prognosis
The transplant-related outcomes are summarized in Table 2. The mean follow-up period was 161 months (range, 2–341 months). Five of the nine patients had recurrent UTI that presented with fever and chills, required admission and treatment with intravenous antibiotics. The minimum number of times of admissions was >3. Urine culture tests were performed for all hospitalized UTI patients. The causative bacteria varied, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Enterococcus faecalis.

Among these patients with recurrent UTIs, three patients progressed to graft failure. One patient underwent allograft removal because of recurrent perigraft abscesses. After allograft removal, the biopsy showed the presence of adenocarcinoma of small bowel origin in the ileal conduit. She received two courses of chemotherapy; however, she died of pneumonia. Two other patients progressed to allograft failure and restarted hemodialysis. One patient sustained a functioning kidney graft; however, he died due to metastasized bladder cancer. Two patients had an episode of acute rejection; however, they recovered successfully with steroid pulse therapy. Six out of nine patients maintained graft function with mean post-transplant serum creatinine levels of 1.0 mL/dL (range, 0.72–1.36 mL/dL) at the last follow-up.

DISCUSSION

The issue of renal transplantation after bladder augmentation surgery has been controversial. Some reports have shown that these patients have increased occurrences of post-transplant complications such as urinary leakage, ureteral stenosis, recurrent UTI, and urinary calculi [7-9]. These complications have been thought to affect the progression of allograft failure.

However, in a recent study, there were no significant differences in urological complication rates after renal transplantation between patients who received bladder augmentation surgery and patients who had not received bladder augmentation surgery [10-14]. The location of ureter implantation during renal transplantation is an important issue. According to some reports, ureteral stenosis could progress more frequently when the allograft ureter was not implanted in the native bladder [15,16]. In our study, the ureter was implanted into the native bladder in six out of nine patients, and there were no differences in ureteral stenosis according to the ureteral implantation site. In patients who undergo kidney transplantation after bladder augmentation surgery, the conventional technique recommends that the transplanted ureter be implanted into the native bladder portion [17,18]. Ureter implantation into the gastrointestinal segment of the enterocystoplasty is a lesser known technique with few reported outcomes. Tan and Tiong [19] reported that implanting the donor ureter into the gastrointestinal segment of the enterocystoplasty appears to be a safe option. In our study, we implanted the ureter into sites where anti-reflux methods could be performed. The ureter implantation was performed into the ileal conduit, stomach, and sigmoid colon in each of the three patients, respectively, and into the native bladder in six patients. Graft function was not associated with the ureter implantation site. Therefore, how the
ureter is implanted is a much more important issue than where the ureter is implanted with respect to the patient’s clinical results.

Recurrent UTIs are known to deteriorate allograft function, and some reports have suggested that post-renal transplant patients with recurrent UTIs tend to have worse graft function. However, their allograft survival rate does not differ from that of the general transplant population [10,20-22]. In our study, however, there were five patients who had recurrent UTIs, and three of them progressed to allograft failure. All patients had recurrent episodes of UTI and were hospitalized for related infections. Therefore, the long-term transplant outcome may depend on the presence of recurrent UTIs. Rigamonti et al. [2] emphasized the use of prophylactic antibiotics on a long-term basis to help reduce infection rates. Their standard practice was to provide long-term antibiotics in all patients with bladder dysfunction following transplantation, for at least 6 months. Therefore, it is necessary to carefully monitor for urinary infection, use antibiotic prophylaxis, and aggressively treat UTIs in these patients. Providing thorough education about pre- and post-transplant CISC is also important.

Several studies have demonstrated that there are no significant differences in graft survival between patients who underwent bladder augmentation surgery and those who did not [10,15,16,23]. Basiri et al. [15] found significant differences in allograft failure between the bladder augmentation group and the control group (P=0.03); however, these differences were due to a higher incidence of acute and chronic rejection in the augmented group than in the control group (41% vs. 33% and 50% vs. 29%, respectively) [15]. Proper immunosuppression, in addition to regular surveillance for urinary tract infection, is important in kidney transplant recipients with a history of bladder augmentation.

This study has several limitations. First, this was a small sample-sized study based on a single-center experience. Second, this was a retrospective, simple case review. Further multicenter studies should be conducted to draw firm conclusions on long-term outcomes of renal transplantations in patients with bladder augmentation cystoplasty. In conclusion, renal transplantation after bladder augmentation cystoplasty in ESRD patients with lower urinary tract dysfunction is considered relatively safe. Ureter implantation with an anti-reflux mechanism is an important surgical technique in these patients. Recurrent UTIs could be the major contributing factor toward graft failure. Therefore, CISC, continuous education on the concept of thorough hygiene, and close monitoring of UTIs should be strengthened.

ACKNOWLEDGMENTS

Conflict of Interest
Sangil Min is an editorial board member of the journal but did not involve in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Funding/Support
This study was supported by research grant from the Korean Society for Transplantation (2020-00-01001-001).

ORCID
Jin Sun Choi https://orcid.org/0000-0002-5001-0739
Hyunmin Ko https://orcid.org/0000-0002-5078-6860
Hyo Kee Kim https://orcid.org/0000-0002-0332-2326
Chris Chung https://orcid.org/0000-0003-4089-8276
Ahram Han https://orcid.org/0000-0002-3866-5214
Seung-Kee Min https://orcid.org/0000-0002-1433-2562
Jongwon Ha https://orcid.org/0000-0003-2285-3517
Sangil Min https://orcid.org/0000-0002-0688-0278

Author Contributions
Conceptualization: SM, AH, JH. Data curation: HK, CC, AH. Formal analysis: HK, CC, SM, SKM. Funding acquisition: SM. Methodology: SM, HKK, JSC. Project administration: SM, SKM, JH. Visualization: HKK, SM, JSC. Writing—original draft: JSC. Writing—review & editing: HK, HKK, CC, AH, SKM, JH, SM.

REFERENCES
1. Power RE, O'Malley KJ, Khan MS, Murphy DM, Hickey DP. Renal transplantation in patients with an augmentation cystoplasty. BJU Int 2000;86:28-31.
2. Rigamonti W, Capizzi A, Zacchello G, Capizzi V, Zanon GF, Montini G, et al. Kidney transplantation into bladder augmentation or urinary diversion: long-term results. Transplantation 2005;80:1435-40.
3. Crowe A, Cairns HS, Wood S, Rudge CJ, Woodhouse CR, Neild GH. Renal transplantation following renal fail-
ure due to urological disorders. Nephrol Dial Transplant 1998;13:2065-9.
4. Mitchell ME, Piser JA. Intestinocystoplasty and total bladder replacement in children and young adults: follow-up in 129 cases. J Urol 1987;138:579-84.
5. Park YJ, Ha J, Min SK, Kim YS, Kim KM, Oh SJ, et al. Experiences of renal transplantation after correction of dysfunctional contracted bladder. J Korean Soc Transplant 2008;22:220-5.
6. Yun IJ, Ha J, Choi Y, Kim KM, Choi H, Kim SJ. Renal transplantation into the gastric augmented bladder. J Korean Soc Transplant 1995;9:193-8.
7. McDougal WS. Metabolic complications of urinary intestinal diversion. J Urol 1992;147:1199-208.
8. Nguyen DH, Bain MA, Salmonson KL, Ganesan GS, Burns MW, Mitchell ME. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993;150(2 Pt 2):707-9.
9. Palmer LS, Franco I, Kogan SJ, Reda E, Gill B, Levitt SB. Urolithiasis in children following augmentation cystoplasty. J Urol 1993;150(2 Pt 2):726-9.
10. Traxel E, DeFoor W, Minevich E, Reddy P, Alam S, Reeves D, et al. Low incidence of urinary tract infections following renal transplantation in children with bladder augmentation. J Urol 2011;186:667-71.
11. Nuininga JE, Feitz WF, van Dael KC, de Gier RP, Cornelissen EA. Urological complications in pediatric renal transplantation. Eur Urol 2001;39:598-602.
12. Otukesh H, Basiri A, Simfoorosh N, Hoseini R, Fereshtehnejad SM, Chalian M. Kidney transplantation in children with posterior urethral valves. J Pediatr Transplant 2008;12:516-9.
13. Lopez Pereira P, Jaureguizar E, Martinez Urrutia MJ, Meseguer C, Navarro M. Does treatment of bladder dysfunction prior to renal transplant improve outcome in patients with posterior urethral valves? Pediatr Transplant 2000;4:118-22.
14. Lopez Pereira P, Ortiz Rodriguez R, Fernandez Camblor C, Martinez Urrutia MJ, Lobato Romera R, Espinosa L, et al. Renal transplant outcome in children with an augmented bladder. Front Pediatr 2013;1:42.
15. Basiri A, Otoukesh H, Simfoorosh N, Hoseini R, Fareskhinejad SM, Chalian M. Kidney transplantation in children with augmentation cystoplasty. J Urol 2007;178:274-7.
16. Nahas WC, Mazzucchi E, Arap MA, Antonopoulos IM, Neto ED, Ianhez LE, et al. Augmentation cystoplasty in renal transplantation: a good and safe option—experience with 25 cases. Urology 2002;60:770-4.
17. Nguyen DH, Reinberg Y, Gonzalez R, Fryd D, Najarian JS. Outcome of renal transplantation after urinary diversion and enterocystoplasty: a retrospective, controlled study. J Urol 1990;144:1349-51.
18. Wang ZZ, Wang C, Cunningham EC, Allen RD, Sharland AF, Bishop GA. Optimized method for ureteric reconstruction in a mouse kidney transplant model. ANZ J Surg 2014;84:481-5.
19. Tan LR, Tiong HY. Ureteric implantation into the bowel portion of augmented bladders during kidney transplantation: a review of urological complications and outcomes. ANZ J Surg 2019;89:930-4.
20. Pereira DA, Barroso U Jr, Machado P, Pestana JO, Rosito TE, Pires J, et al. Effects of urinary tract infection in patients with bladder augmentation and kidney transplantation. J Urol 2008;180:2607-10.
21. Abbott KC, Swanson SJ, Richter ER, Bohen EM, Agodaa LY, Peters TG, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004;44:353-62.
22. Graversen ME, Dalgard LS, Jensen-Fangel S, Jesspersen B, Østergaard L, Seggaard OS. Risk and outcome of pyelonephritis among renal transplant recipients. BMC Infect Dis 2016;16:264.
23. Taghizadeh AK, Desai D, Ledermann SE, Shroff R, Marks SD, Koffman G, et al. Renal transplantation or bladder augmentation first? A comparison of complications and outcomes in children. BJU Int 2007;100:1365-70.